ARGXargenxFinished
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 184 (final count)
- Started
- Apr 26, 2021
- Main results expected
- Dec 31, 2024
- Fully finished
- Dec 31, 2024
- Results posted
- Jan 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of AEs, SAEs and AESIs
Measured over: Up to 3.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04818671 · record last updated 2026-01-22 · checked 2026-11-09 15:47 UTC